Prostate cancer is one of the most common malignant tumors among men and has ranked among the leading cancers in Taiwan in recent years. With an aging population and increasing awareness of early detection, achieving accurate diagnosis at an early stage has become a critical challenge for clinicians and the medical community. Against this backdrop,…
Dr. Ya-Yao Huang, CEO of Primo Biotechnology, was invited to deliver a keynote lecture at the American Association for Cancer Research (AACR), one of the world’s leading organizations dedicated to cancer research. Lecture Topic: Molecular Imaging: Update on PET Imaging in Oncological Research Dr. Huang will share innovative developments in radiopharmaceuticals and their clinical applications,…
Primo has long been dedicated to advancing the field of nuclear medicine, constantly pushing the boundaries of innovation and quality. This year, we are proud to take the stage at the 2025 Annual Conference of Society of Nuclear Medicine, where our latest research has been officially recognized and featured—marking another milestone in our journey of…
Primo Biotechnology Co., Ltd., a pioneering developer of Radioligand Drug Conjugates (RDCs), announced today the signing of a Memorandum of Understanding (MoU) with AnBogen Therapeutics, Inc., a prominent biotech firm specializing in novel drug development. The two companies will jointly develop and manufacture an innovative peptide-based radioligand therapeutic, targeting solid tumors diagnosis and treatment —…
Primo Biotechnology Co., Ltd., a pioneering developer of radiopharmaceuticals, today announced a strategic partnership with Terthera B.V., a radionuclide production-focused company based in The Netherlands. Under the agreement, Terthera will supply Primo with high-purity, non-carrier-added (NCA), GMP-grade Terbium-161 (Tb-161), a next-generation therapeutic radionuclide. Primo has also secured exclusive distribution rights for Tb-161 in Taiwan. This…
Primo Biotechnology Co., Ltd., a pioneering radiopharmaceutical company in Taiwan, announced the successful completion of its NT$220 million Series A funding round. With total capital raised now exceeding NT$500 million, including seed and early-stage investments, Primo is accelerating its path toward leadership in radioligand theranostics. The company also revealed plans to launch its IPO in…
Taipei, Taiwan – Primo Biotechnology Co., Ltd. (“Primo”) proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration (TFDA) and has been award dual certification for PIC/S GMP and GDP. This achievement demonstrates Primo’s dedication to meeting international quality standards for nuclear medicine production and sets the stage…
Taipei, Taiwan, March 19, 2025 – In response to the growing burden of prostate cancer in Taiwan, Primo Biotechnology Co., Ltd. (“Primo”) has formed a strategic partnership with Germany-based ABX advanced biochemical compounds GmbH (ABX) to lay the groundwork for introducing PB01 to the Taiwanese market. Data from Taiwan Cancer Registry indicate a steady increase…
Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies Taipei, Taiwan – Primo Biotechnology (“Primo”) today announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear medicine production. The partnership includes a supply and exclusive distribution agreement to introduce Ilumira (n.c.a. lutetium-177, Lu-177), SHINE’s high-purity therapeutic isotope,…
Taipei, Taiwan – Primo Biotechnology Co., Ltd., a leader in precision medicine and radioligand theranostics (RLT), is proud to announce its collaboration with Antelope Surgical Solutions, Inc., a pioneering biotechnology company based in New York, USA. This partnership will facilitate the world’s first FDA-approved Phase I/II clinical trial of AS1986NS, an innovative fluorescent imaging agent…
1Chi-Wei Chang,1 Hsin-En Tsai, 2Ching-Huang Lo, 1Ya-Yao Huang* 1 Primo Biotechnology Co., Ltd., Taipei, Taiwan 2 Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan This study poster was presented at 2024 Annual Conference of Society of Nuclear Medicine, Taiwan. This study reports on the GMP-compliant process for the preparation of [18F]PSMA-1007 using a Neptis RS…
1Yen-Hsiang Chang, 2Hao Lun Luo, 3Li Yu Chen, 3Shiang Ling Lin, 3Ya Ting Huang 1 Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan. 2 Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan. 3 Primo Biotechnology Co., Ltd, Taipei, Taiwan. This study poster was presented at 2024 Annual Conference of Society of Nuclear…
